We are thrilled to share exciting news from ourMargaret West Comprehensive Breast Center and its Director, Dr. Richard Fine.
The FDA has granted marketing authorization for ProSense® cryoablation, a minimally invasive, outpatient treatment option for select patients with early-stage, low-risk breast cancer.
This groundbreaking decision was supported by data from the pivotal ICE3 clinical trial, for which Dr. Fine served as lead author. The ICE3 trial demonstrated that cryoablation, when combined with adjuvant endocrine therapy, provides safe and effective outcomes comparable to lumpectomy — with the added benefits of less surgery, faster recovery, and excellent cosmetic results.
“The ICE3 study has proven that cryoablation with ProSense is a safe, minimally invasive ablative procedure with results similar to that of lumpectomy patients who took endocrine therapy and has the benefit of being an office-based, nonsurgical treatment,” said Dr. Fine.
This advancement marks an important step forward in the de-escalation of breast cancer care, offering patients effective treatment with reduced invasiveness and improved quality of life.
We are incredibly proud of Dr. Fine’s leadership and the contributions of the entire Margaret West Breast Center team in advancing patient-centered, evidence-based innovation.
Click the link below to read the full article: